Arnaub Chatterjee is Chief Product and Solutions Officer at TriNetX where he is building novel software and data science capabilities to advance clinical development and patient care in the life sciences industry. In addition, Arnaub is passionate about teaching and is a member of the faculties in the Department of Health Care Policy at Harvard Medical School in the Department of Policy Analysis and Management at Cornell University.

Prior to Medidata, Arnaub was Associate Partner in the Pharmaceutical and Medical Products group at McKinsey & Company, where he advised pharmaceutical and technology companies on a range of topics, including real world evidence and leveraging analytics in research and development. Before his time at McKinsey, he served as Director of Data Science and Insights for Merck’s Center for Real World Evidence. He previously served as a technology advisor in the Obama Administration in the Department of Health and Human Services (HHS) as well as a lead policy analyst on healthcare fraud and abuse initiatives around the Affordable Care Act. Prior to government service, he was a strategy consultant at Deloitte Consulting, supporting organizations on health technology strategy.

His work has been published in multiple peer-reviewed journals such as the Harvard Business Review and Nature and he has presented at conferences ranging from South by Southwest to the American College of Cardiology. Arnaub serves as an advisor and board member to a number of organizations, including the World Economic Forum’s Council for Biotechnology and CityPods, a solution to scale temporary housing. He holds graduate degrees in health administration (MHA) and public administration (MPA) from Cornell University, and received his undergraduate degree from the University of Michigan.

Michelle Dipp is a Co-Founder and Managing Partner at Biospring Partners. Michelle has over a decade of healthcare private equity and venture capital expertise. She currently serves on the Board of Directors of two Biospring portfolio companies, Abzena and Kiniciti.

Michelle was previously a Managing Director at General Atlantic where she launched the firm’s first life sciences investment platform. At General Atlantic, Michelle led multiple investments including Ginkgo BioWorks (NYSE: DNA), Motif FoodWorks, PathAI, Immunocore (NASDAQ: IMCR) and Ocumension (HK: 1477). Prior to General Atlantic, Michelle was Co-Founder and General Partner of Longwood Fund, a leading healthcare investment firm based in Boston.

Prior to Longwood, Michelle was the Senior Vice President of the CEEDD at GlaxoSmithKline (NASDAQ: GSK), leading global business development and M&A.

Michelle holds a Bachelor of Medicine and Bachelor of Surgery from the University of Oxford Medical School and a Doctor of Philosophy in Human Physiology from the University of Oxford.

Born and raised in El Paso, Texas, Michelle is passionate about education and healthcare in underserved populations. Michelle serves on the following Boards:

Board of Directors, Women’s Foundation of Boston, focused on underprivileged women and girls

Board of Trustees, Xavier University of Louisiana

Trustee Advisory Board, Beth Israel Deaconess Medical Center

Board of Directors, Life Science Cares, focused on alleviating poverty

Jennifer Lum is a Co-Founder and Managing Partner at Biospring Partners. She is an accomplished entrepreneur and investor. She has co-founded several companies and has worked with many others on formation, fundraising, growth, and M&A.

Jennifer is a Venture Capital Advisor at Harvard Business School and an Advisor at MIT’s Martin Trust Center for Entrepreneurship. She is also an Advisory Board member at The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

Jennifer co-founded Forge.AI (acquired by FiscalNote) and Adelphic (acquired by Time). She was an early team member at Quattro Wireless (acquired by Apple), m-Qube (acquired by VeriSign), and WebHosting.com (acquired by AT&T). She has also held various roles as a management consultant with financial services and technology companies.

Prior investments in Life Sciences Technology companies include: ResearchGate, Volta Labs, Nomic.

Jennifer grew up in Toronto, Canada. She is a big fan of 🎶🎾🍣✈️.

Andrew C. Pearson is the Chief Operating Officer at Biospring Partners. Mr. Pearson has 25 years of experience in global private equity. Mr. Pearson served as Managing Director, Chairman of the Portfolio Committee and Global Head of Portfolio Management with General Atlantic, one of the world's largest global growth equity firms with over $40 billion under management and 14 offices on four continents. As Chairman of the Portfolio Committee, Mr. Pearson was charged with establishing and executing the firm's global liquidity and value-creation targets as well as developing risk management parameters.

Prior to joining General Atlantic, Mr. Pearson was a Business Analyst at McKinsey & Company, Inc. Mr. Pearson serves as Treasurer and Board Member of the Blossom Hill Foundation, a non-profit which provides fellowships to social entrepreneurs who develop ideas to help children affected by conflict. He received an M.A. and B.A. in Regional Science from The School of Arts and Sciences at the University of Pennsylvania and a B.S. in Finance, Magna Cum Laude, from The Wharton School at the University of Pennsylvania.

Ryan Neubauer is the Head of Finance at Biospring Partners. Ryan has 14 years of experience in the Alternative Asset Management Industry, and comes to Biospring following 9 years with General Atlantic.

During his time at General Atlantic, Ryan held two Controllership positions, most recently working on the Corporate Holding Company, and for the General Partnership Funds before that. While there, Ryan also served as an advisor for Echoing Green, a non-profit organization that provides seed-funding and leadership development to Fellows seeking to be change agents in their communities.

Prior to joining General Atlantic, Ryan was a Manager in Ernst & Young’s Wealth & Asset Management Practice, where he primarily served Audit & Assurance clients in the New York area, and also completed two international secondments with the Global Advisory Practice, assisting on projects in Australia and the U.K. ​

Ryan graduated from Fairfield University with both a Masters and a Bachelors of Science in Accounting, and is a Certified Public Accountant in the State of Connecticut, where he resides with his wife and three kids. Ryan enjoys running, skiing, golfing, traveling, and the beach.

With law firm, regulatory and in-house experience, I have excelled at providing legal counsel to rapidly growing organizations. Business savvy and Series 7 and 24 licensed, I have extensive experience in:

Corporate Governance | Investment Advisory and Broker Dealer Law | Compliance | Mergers and Acquisition | Commercial Banking | Litigation Management | Securities | Human Resources | Technology | Insurance

My career began with the Comptroller of the Currency, the regulator of national banks, followed by the position of Chief Counsel at the PA Department of Banking. At Schnader Harrison, I was a partner in the business department and the co-chair of the firm's Financial Institutions Practice Group. In that role, I represented banks, trust companies and a variety of securities firms.

After participating in the formation of the Lockwood family of companies, I joined them in the role of general counsel where I spend the next 13 years in a period of significant growth in AUM / AUA.

John Sexton is President Emeritus of New York University, the Dean Emeritus of NYU Law School, and the Benjamin Butler Professor of Law. He joined the Law School faculty in 1981, was named the School's Dean in 1988; he served in this capacity for fourteen years. He was named the University's President in 2001, and served in that capacity until January 1, 2016.

In addition to his work as President Emeritus, Sexton currently serves as the CEO of the Catalyst Foundation for Universal Education, Chair of the University of the People President's Council, and Chair of the Mary Christie Foundation. a member of the American Academy of Arts and Sciences, and a member of the Council on Foreign Relations. He is a member of the board of the Institute of International Education, the College Advising Corps, and the Board of Trustees of Trinity School, New York City.

Robert Charles Pozen known as "Bob" (born 1946) is an American financial executive with a strong interest in public policy. Pozen currently teaches executives about how to be more productive and serves as an executive coach and mentor, www.bobpozen.com. He is the former chairman of MFS Investment Management, the oldest mutual fund company in the United States. Previously, Pozen was the President of Fidelity Investments. As of 2020 he is a senior lecturer at MIT Sloan School of Management, and a senior fellow at the Brookings Institution.

Pozen grew up in Bridgeport, Connecticut, where he attended public high school and won a scholarship to attend Harvard College. In 1968, he graduated summa cum laude and Phi Beta Kappa from Harvard, which awarded him a Knox Traveling Fellowship.

In 1972, Pozen received a J.D. degree from Yale Law School, where he served on the editorial board of the Yale Law Journal. He received a JSD from Yale in 1973 for his doctoral thesis on state enterprises in Africa. He is a member of the Massachusetts, New York and Washington, D.C. bars.

He has been married for more than 40 years to Elizabeth Kelner Pozen, a psychotherapist and figurative painter. They live in Boston, Massachusetts, and have two adult children.

Colin Raney is the Chief Marketing Officer of PillPack. Prior to PillPack, he served as CMO of Formlabs a 3D printing company founded at the MIT Media Lab. He also spent 8-years at IDEO, serving as the Managing Director of IDEO Boston and an Associate Partner within the firm. At IDEO, Raney helped to pioneer the Business Design discipline, which uses design methodologies to develop new business ventures. He has written for the Harvard Business Review and Fast Company. He holds an MBA from Carnegie Mellon.

John is the Chief Technology Officer of Integral. He has over 39 years of experience in the pharmaceutical industry—29 years at GSK R&D including 11 years on its executive leadership team. John has participated in the research and development of scores of commercial products. John’s most recent roles before Integral were SVP of GSK’s science and technology platforms and SVP of a small in silico drug discovery unit. John is a proponent of seeking, integrating and implementing innovative approaches to drug discovery and development. He led several GSK innovation initiatives through internal teams, technology acquisitions and partnerships. John conceptualized and is currently senior science advisor to the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium – an open membership, public/private partnership currently comprised of Pharma, Tech, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. John is also Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention and innovation in artificial intelligence. John received his PhD from Penn State University in biological chemistry.

Katie Burke is the Chief People Officer at HubSpot where she manages the teams responsible for delivering a remarkable and inclusive candidate and employee experience. During her time leading people initiatives at HubSpot, the company has been named the #1 Best Place to Work by Glassdoor, the #1 Best Place to Work for Women by Comparably, and a Best Place to Work for Parents by Fortune.

Prior to her current role, Katie started HubSpot’s culture team and oversaw global communications during the company’s IPO. Before joining HubSpot, Katie was the Director of Marketing and Corporate Partnerships at Athletes’ Performance (EXOS) and a Director at the Glover Park Group. She attended Bates College and holds an MBA from MIT’s Sloan School of Management.

Katie serves on the board of Paycor, and as an advisor to Biospring Partners and 826 Boston.

Peter Blair Henry is the Class of 1984 Senior Fellow at Stanford University’s Hoover Institution, Senior Fellow at Stanford’s Freeman Spogli Institute for International Studies (FSI), and Dean Emeritus of New York University’s Leonard N. Stern School of Business. The youngest person ever named to the Stern Deanship, Peter served as Dean from January 2010 through December 2017 and doubled the school’s average annual fundraising. Formerly the Konosuke Matsushita Professor of International Economics at Stanford University’s Graduate School of Business, from 2001–2006 Peter’s research was funded by an NSF CAREER Award, and he has authored numerous peer-reviewed articles in the flagship journals of economics and finance, as well as a book on global economic policy, Turnaround: Third World Lessons for First World Growth (Basic Books).

A Vice Chair of the Boards of the National Bureau of Economic Research and the Economic Club of New York, Peter also serves on the Boards of Citigroup and Nike. In 2015, he received the Foreign Policy Association Medal, the highest honor bestowed by the organization, and in 2016 he was honored as one of the Carnegie Foundation’s Great Immigrants.

With financial support from the Hoover Institution and the Alfred P. Sloan Foundation, Peter leads the Ph.D. Excellence Initiative (PhDEI), a post-baccalaureate program designed to address underrepresentation in economics by mentoring exceptional students of color interested in pursuing doctoral studies in the field. For his leadership of the PhDEI, Peter received the 2022 Impactful Mentoring Award from the American Economic Association. Peter received his PhD in economics from MIT and Bachelor’s degrees from Oxford University, where he was a Rhodes Scholar, and the University of North Carolina at Chapel Hill, where he was a Morehead-Cain Scholar, a member of Phi Beta Kappa, a reserve wide receiver on the football team, and a finalist in the 1991 campus-wide slam dunk competition.

Born in Kingston, Jamaica, in 1969, Peter became a U.S. citizen in 1986. He lives in Stanford and Düsseldorf with his wife and four sons.

Ms. Wang is CIO Portfolio Implementation, a member of the PM management committee, and a managing director in the Newport Beach office. She oversees portfolio implementation, portfolio management analytics, and the PM data delivery platform. She is also a portfolio manager for PIMCO’s global macro hedge fund strategies and a member of the Investment Committee. Prior to joining PIMCO in 2010, she was with HBK Capital Management for 11 years, most recently as a managing director and partner responsible for developed market fixed income. Ms. Wang was previously a fixed income analyst at Lehman Brothers. She has 27 years of investment experience and holds a bachelor's degree in economics and molecular biochemistry and biophysics from Yale University.

Dr. Maulik Majmudar is a cardiologist and co-founder and Chief Medical Officer at Biofourmis. Prior to joining Biofourmis, Dr. Majmudar was the Medical Officer for Amazon Halo and led the development and launch of Amazon’s first health membership service. Prior to Amazon, he was Associate Director of the Healthcare Transformation Lab at Massachusetts General Hospital, and an Assistant Professor at Harvard Medical School, where he was responsible for the identification, validation, and implementation of digital health solutions to improve care delivery as well as the patient and provider experience. While at MGH, he was awarded an education grant from the Aetna Foundation to launch a new Fellowship in Healthcare Innovation, aimed at fostering the next generation of clinician innovators.

Dr. Majmudar was also a founding member and chief clinical officer of Quanttus, Inc. a venture-backed medical wearables startup that was developing a novel wrist-based device for continuous cuffless blood pressure monitoring.

Dr. Majmudar attended Northwestern University Feinberg School of Medicine and then completed residency training in Internal Medicine at The Johns Hopkins Hospital, followed by a cardiovascular medicine fellowship at the Brigham and Women’s Hospital. He also holds two patents and has had several publications in high-impact journals, such as Nature, Circulation, JAMA, and Journal of Healthcare Delivery and Implementation Science.

Sir John Irving Bell GBE FRS FMedSci FREng (born 1 July 1952) is a Canadian immunologist and geneticist. From 2006 to 2011, he was President of the United Kingdom's Academy of Medical Sciences, and since 2002 he has held the Regius Chair of Medicine at the University of Oxford. He was since 2006 Chairman of the Office for Strategic Coordination of Health Research (OSCHR) but in 2020 became a normal member. Bell was selected to the Vaccine Taskforce sometime before 1 July 2020. Bell is also on the board of directors of the SOE quango Genomics England.

Bell was born in Edmonton, Alberta, where his parents worked in haematology and pharmacy. He attended Ridley College in St. Catharines, Ontario. He graduated from the University of Alberta in 1975, and then studied medicine on a Rhodes Scholarship at Magdalen College, Oxford. In 1978 he rowed in the Oxford University Lightweight Rowing Club Blue Boat which raced against Cambridge University.

In 1982, he took up a position as Clinical Fellow in Immunology with Hugh McDevitt at Stanford University, where he worked on histocompatibility antigens and autoimmune disease.

In 1987, Bell returned to Oxford as a Wellcome Trust Senior Clinical Fellow, and joined the Institute of Molecular Medicine, founded by David Weatherall. In 1992 he succeeded Weatherall as the Nuffield Professor of Clinical Medicine and, in 2002, became the Regius Professor of Medicine at Oxford, also after Weatherall. In 1994, Bell was one of the founders of the Wellcome Trust Centre for Human Genetics at Oxford University. He is an emeritus fellow of Magdalen College, Oxford. Bell is also the senior member of the Oxford University Women's Boat Club Executive Committee and is a member of the Governing Body of Christ Church, Oxford. He sat on the Council of the Medical Research Council between 1998 and 2003. Since 2011, Bell has been one of two Life Sciences Champions for the UK.

Socrates Zacharias is a Vice President at Biospring Partners. Prior to Biospring, Socrates spent several years on the Translational Sciences team at UPMC Enterprises, which is the investment and commercialization arm of UPMC. During his time at UPMCE, Socrates worked on venture investments across the life sciences as well as supporting company-formation efforts.

Socrates comes from an investment banking background, having previously worked at Leerink Partners (now SVB Securities) where he focused on public and private capital raises and M&A for emerging biotech companies. Subsequent to Leerink, he worked at PNC Capital Markets advising companies on financing strategies and capital structures.

Socrates graduated from Carnegie Mellon University with a B.S. in Biological Sciences and Psychology and an M.S. in Biotechnology and Management.

Alex Pfeffer is an Associate at Biospring Partners. Prior to Biospring, Alex spent two years at Macquarie in the Software & Services group.

Alex graduated from Vanderbilt University with a B.A. in Economics and a minor in Business.

John Quintas is a Project Manager at Biospring Partners. Prior to Biospring, John led various advertising and analytics initiatives for brands like Google, Microsoft, and Uber.

John graduated from Northeastern University with a B.A. in International Affairs and Economics.

Precious Brown is an Executive Assistant and Office Manager at Biospring Partners. Precious has spent many years in the financial services industry. Prior to Biospring, Precious spent ten years at General Atlantic in the Healthcare and Life Sciences group.